<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33322643</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>24</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Dec</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">9457</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21249457</ELocationID>
        <Abstract>
          <AbstractText>Breast cancer is the most common cancer among women worldwide. Although the five-, ten- and fifteen-year survival rates are good for breast cancer patients diagnosed with early-stage disease, some cancers recur many years after completion of primary therapy. Tumor heterogeneity and clonal evolution may lead to distant metastasis and therapy resistance, which are the main causes of breast cancer-associated deaths. In the clinic today, imaging techniques like mammography and tissue biopsies are used to diagnose breast cancer. Even though these methods are important in primary diagnosis, they have limitations when it comes to longitudinal monitoring of residual disease after treatment, disease progression, therapy responses, and disease recurrence. Over the last few years, there has been an increasing interest in the diagnostic, prognostic, and predictive potential of circulating cancer-derived material acquired through liquid biopsies in breast cancer. Thanks to the development of sensitive devices and platforms, a variety of tumor-derived material, including circulating cancer cells (CTCs), circulating DNA (ctDNA), and biomolecules encapsulated in extracellular vesicles, can now be extracted and analyzed from body fluids. Here we will review the most recent studies on breast cancer, demonstrating the clinical potential and utility of CTCs and ctDNA. We will also review literature illustrating the potential of circulating exosomal RNA and proteins as future biomarkers in breast cancer. Finally, we will discuss some of the advantages and limitations of liquid biopsies and the future perspectives of this field in breast cancer management.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tellez-Gabriel</LastName>
            <ForeName>Marta</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Biology, Faculty of Health Sciences, UiT-The Arctic University of Norway, 9011 Tromsø, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Knutsen</LastName>
            <ForeName>Erik</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-4903-0150</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medical Biology, Faculty of Health Sciences, UiT-The Arctic University of Norway, 9011 Tromsø, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Perander</LastName>
            <ForeName>Maria</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Biology, Faculty of Health Sciences, UiT-The Arctic University of Norway, 9011 Tromsø, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055354" MajorTopicYN="N">Exosomes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="N">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">breast cancer</Keyword>
        <Keyword MajorTopicYN="N">circulating tumor DNA</Keyword>
        <Keyword MajorTopicYN="N">circulating tumor cells</Keyword>
        <Keyword MajorTopicYN="N">exosomes</Keyword>
        <Keyword MajorTopicYN="N">liquid biopsy</Keyword>
        <Keyword MajorTopicYN="N">prediction</Keyword>
        <Keyword MajorTopicYN="N">prognosis</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>1</Hour>
          <Minute>4</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33322643</ArticleId>
        <ArticleId IdType="pmc">PMC7763984</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms21249457</ArticleId>
        <ArticleId IdType="pii">ijms21249457</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21492</ArticleId>
            <ArticleId IdType="pubmed">30207593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harbeck N., Penault-Llorca F., Cortes J., Gnant M., Houssami N., Poortmans P., Ruddy K., Tsang J., Cardoso F. Breast cancer. Nat. Rev. Dis Primers. 2019;5:66. doi: 10.1038/s41572-019-0111-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41572-019-0111-2</ArticleId>
            <ArticleId IdType="pubmed">31548545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer in Norway 2018—Cancer Incidence, Mortality, Survival and Prevalence in Norway. Cancer Registry of Norway; Oslo, Norway: 2019. </Citation>
        </Reference>
        <Reference>
          <Citation>Sestak I., Cuzick J. Markers for the identification of late breast cancer recurrence. Breast Cancer Res. 2015;17:10. doi: 10.1186/s13058-015-0516-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13058-015-0516-0</ArticleId>
            <ArticleId IdType="pmc">PMC4307995</ArticleId>
            <ArticleId IdType="pubmed">25848913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan H., Gray R., Braybrooke J., Davies C., Taylor C., McGale P., Peto R., Pritchard K.I., Bergh J., Dowsett M., et al.  20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N. Engl. J. Med. 2017;377:1836–1846. doi: 10.1056/NEJMoa1701830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1701830</ArticleId>
            <ArticleId IdType="pmc">PMC5734609</ArticleId>
            <ArticleId IdType="pubmed">29117498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA. 2001;98:10869–10874. doi: 10.1073/pnas.191367098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.191367098</ArticleId>
            <ArticleId IdType="pmc">PMC58566</ArticleId>
            <ArticleId IdType="pubmed">11553815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al.  Molecular portraits of human breast tumours. Nature. 2000;406:747–752. doi: 10.1038/35021093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35021093</ArticleId>
            <ArticleId IdType="pubmed">10963602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarke M., Collins R., Darby S., Davies C., Elphinstone P., Evans V., Godwin J., Gray R., Hicks C., James S., et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;366:2087–2106. doi: 10.1016/S0140-6736(05)67887-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(05)67887-7</ArticleId>
            <ArticleId IdType="pubmed">16360786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies C., Pan H., Godwin J., Gray R., Arriagada R., Raina V., Abraham M., Medeiros Alencar V.H., Badran A., Bonfill X., et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–816. doi: 10.1016/S0140-6736(12)61963-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(12)61963-1</ArticleId>
            <ArticleId IdType="pmc">PMC3596060</ArticleId>
            <ArticleId IdType="pubmed">23219286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nik-Zainal S., Van Loo P., Wedge D.C., Alexandrov L.B., Greenman C.D., Lau K.W., Raine K., Jones D., Marshall J., Ramakrishna M., et al.  The life history of 21 breast cancers. Cell. 2012;149:994–1007. doi: 10.1016/j.cell.2012.04.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.04.023</ArticleId>
            <ArticleId IdType="pmc">PMC3428864</ArticleId>
            <ArticleId IdType="pubmed">22608083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baslan T., Kendall J., Volyanskyy K., McNamara K., Cox H., D’Italia S., Ambrosio F., Riggs M., Rodgers L., Leotta A., et al.  Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing. eLife. 2020;9 doi: 10.7554/eLife.51480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.51480</ArticleId>
            <ArticleId IdType="pmc">PMC7220379</ArticleId>
            <ArticleId IdType="pubmed">32401198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Waters J., Leung M.L., Unruh A., Roh W., Shi X., Chen K., Scheet P., Vattathil S., Liang H., et al.  Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014;512:155–160. doi: 10.1038/nature13600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13600</ArticleId>
            <ArticleId IdType="pmc">PMC4158312</ArticleId>
            <ArticleId IdType="pubmed">25079324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graham L.J., Shupe M.P., Schneble E.J., Flynt F.L., Clemenshaw M.N., Kirkpatrick A.D., Gallagher C., Nissan A., Henry L., Stojadinovic A., et al.  Current approaches and challenges in monitoring treatment responses in breast cancer. J. Cancer. 2014;5:58–68. doi: 10.7150/jca.7047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/jca.7047</ArticleId>
            <ArticleId IdType="pmc">PMC3881221</ArticleId>
            <ArticleId IdType="pubmed">24396498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marinovich M.L., Bernardi D., Macaskill P., Ventriglia A., Sabatino V., Houssami N. Agreement between digital breast tomosynthesis and pathologic tumour size for staging breast cancer, and comparison with standard mammography. Breast. 2019;43:59–66. doi: 10.1016/j.breast.2018.11.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.breast.2018.11.001</ArticleId>
            <ArticleId IdType="pubmed">30466027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marinovich M.L., Houssami N., Macaskill P., Sardanelli F., Irwig L., Mamounas E.P., von Minckwitz G., Brennan M.E., Ciatto S. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J. Natl. Cancer Inst. 2013;105:321–333. doi: 10.1093/jnci/djs528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djs528</ArticleId>
            <ArticleId IdType="pubmed">23297042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marinovich M.L., Sardanelli F., Ciatto S., Mamounas E., Brennan M., Macaskill P., Irwig L., von Minckwitz G., Houssami N. Early prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of the accuracy of MRI. Breast. 2012;21:669–677. doi: 10.1016/j.breast.2012.07.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.breast.2012.07.006</ArticleId>
            <ArticleId IdType="pubmed">22863284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pennant M., Takwoingi Y., Pennant L., Davenport C., Fry-Smith A., Eisinga A., Andronis L., Arvanitis T., Deeks J., Hyde C. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol. Assess. 2010;14:1–103. doi: 10.3310/hta14500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3310/hta14500</ArticleId>
            <ArticleId IdType="pubmed">21044553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerlinger M., Rowan A.J., Horswell S., Math M., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012;366:883–892. doi: 10.1056/NEJMoa1113205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1113205</ArticleId>
            <ArticleId IdType="pmc">PMC4878653</ArticleId>
            <ArticleId IdType="pubmed">22397650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beca F., Polyak K. Intratumor Heterogeneity in Breast Cancer. Adv. Exp. Med. Biol. 2016;882:169–189. doi: 10.1007/978-3-319-22909-6_7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-319-22909-6_7</ArticleId>
            <ArticleId IdType="pubmed">26987535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Do H., Dobrovic A. Sequence artifacts in DNA from formalin-fixed tissues: Causes and strategies for minimization. Clin. Chem. 2015;61:64–71. doi: 10.1373/clinchem.2014.223040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1373/clinchem.2014.223040</ArticleId>
            <ArticleId IdType="pubmed">25421801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tellez-Gabriel M., Brown H.K., Young R., Heymann M.F., Heymann D. The Challenges of Detecting Circulating Tumor Cells in Sarcoma. Front. Oncol. 2016;6:202. doi: 10.3389/fonc.2016.00202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2016.00202</ArticleId>
            <ArticleId IdType="pmc">PMC5013264</ArticleId>
            <ArticleId IdType="pubmed">27656422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liotta L.A., Saidel M.G., Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 1976;36:889–894.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1253177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butler T.P., Gullino P.M. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 1975;35:512–516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1090362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magbanua M.J.M., Rugo H.S., Wolf D.M., Hauranieh L., Roy R., Pendyala P., Sosa E.V., Scott J.H., Lee J.S., Pitcher B., et al.  Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance) Clin. Cancer Res. 2018;24:1486–1499. doi: 10.1158/1078-0432.CCR-17-2312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-2312</ArticleId>
            <ArticleId IdType="pmc">PMC5856614</ArticleId>
            <ArticleId IdType="pubmed">29311117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strati A., Nikolaou M., Georgoulias V., Lianidou E.S. Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients. Cells. 2019;8:652.  doi: 10.3390/cells8070652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8070652</ArticleId>
            <ArticleId IdType="pmc">PMC6679222</ArticleId>
            <ArticleId IdType="pubmed">31261917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayes D.F., Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Miller M.C., Matera J., Allard W.J., Doyle G.V., Terstappen L.W. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 2006;12:4218–4224. doi: 10.1158/1078-0432.CCR-05-2821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-05-2821</ArticleId>
            <ArticleId IdType="pubmed">16857794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cristofanilli M., Hayes D.F., Budd G.T., Ellis M.J., Stopeck A., Reuben J.M., Doyle G.V., Matera J., Allard W.J., Miller M.C., et al.  Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 2005;23:1420–1430. doi: 10.1200/JCO.2005.08.140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.08.140</ArticleId>
            <ArticleId IdType="pubmed">15735118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., Reuben J.M., Doyle G.V., Allard W.J., Terstappen L.W., et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004;351:781–791. doi: 10.1056/NEJMoa040766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa040766</ArticleId>
            <ArticleId IdType="pubmed">15317891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pierga J.Y., Bidard F.C., Mathiot C., Brain E., Delaloge S., Giachetti S., de Cremoux P., Salmon R., Vincent-Salomon A., Marty M. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin. Cancer Res. 2008;14:7004–7010. doi: 10.1158/1078-0432.CCR-08-0030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-08-0030</ArticleId>
            <ArticleId IdType="pubmed">18980996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bidard F.C., Proudhon C., Pierga J.Y. Circulating tumor cells in breast cancer. Mol. Oncol. 2016;10:418–430. doi: 10.1016/j.molonc.2016.01.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molonc.2016.01.001</ArticleId>
            <ArticleId IdType="pmc">PMC5528978</ArticleId>
            <ArticleId IdType="pubmed">26809472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martos T., Casadevall D., Albanell J. Circulating Tumor Cells: Applications for Early Breast Cancer. Adv. Exp. Med. Biol. 2020;1220:135–146. doi: 10.1007/978-3-030-35805-1_9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-030-35805-1_9</ArticleId>
            <ArticleId IdType="pubmed">32304084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pachmann K., Schuster S. The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients. Cancers (Basel) 2018;10:407.  doi: 10.3390/cancers10110407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers10110407</ArticleId>
            <ArticleId IdType="pmc">PMC6266844</ArticleId>
            <ArticleId IdType="pubmed">30380648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medford A.J., Dubash T.D., Juric D., Spring L., Niemierko A., Vidula N., Peppercorn J., Isakoff S., Reeves B.A., LiCausi J.A., et al.  Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. NPJ Precis. Oncol. 2019;3:18. doi: 10.1038/s41698-019-0090-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41698-019-0090-5</ArticleId>
            <ArticleId IdType="pmc">PMC6635494</ArticleId>
            <ArticleId IdType="pubmed">31341951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabriel M.T., Calleja L.R., Chalopin A., Ory B., Heymann D. Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation. Clin. Chem. 2016;62:571–581. doi: 10.1373/clinchem.2015.249706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1373/clinchem.2015.249706</ArticleId>
            <ArticleId IdType="pubmed">26896446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma S., Zhuang R., Long M., Pavlovic M., Kang Y., Ilyas A., Asghar W. Circulating tumor cell isolation, culture, and downstream molecular analysis. Biotechnol. Adv. 2018;36:1063–1078. doi: 10.1016/j.biotechadv.2018.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biotechadv.2018.03.007</ArticleId>
            <ArticleId IdType="pmc">PMC5971144</ArticleId>
            <ArticleId IdType="pubmed">29559380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Habli Z., AlChamaa W., Saab R., Kadara H., Khraiche M.L. Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities. Cancers (Basel) 2020;12:930.  doi: 10.3390/cancers12071930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12071930</ArticleId>
            <ArticleId IdType="pmc">PMC7409125</ArticleId>
            <ArticleId IdType="pubmed">32708837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Racila E., Euhus D., Weiss A.J., Rao C., McConnell J., Terstappen L.W., Uhr J.W. Detection and characterization of carcinoma cells in the blood. Proc. Natl. Acad. Sci. USA. 1998;95:4589–4594. doi: 10.1073/pnas.95.8.4589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.95.8.4589</ArticleId>
            <ArticleId IdType="pmc">PMC22534</ArticleId>
            <ArticleId IdType="pubmed">9539782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keller L., Werner S., Pantel K. Biology and clinical relevance of EpCAM. Cell Stress. 2019;3:165–180. doi: 10.15698/cst2019.06.188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15698/cst2019.06.188</ArticleId>
            <ArticleId IdType="pmc">PMC6558934</ArticleId>
            <ArticleId IdType="pubmed">31225512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banko P., Lee S.Y., Nagygyorgy V., Zrinyi M., Chae C.H., Cho D.H., Telekes A. Technologies for circulating tumor cell separation from whole blood. J. Hematol. Oncol. 2019;12:48. doi: 10.1186/s13045-019-0735-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-019-0735-4</ArticleId>
            <ArticleId IdType="pmc">PMC6518774</ArticleId>
            <ArticleId IdType="pubmed">31088479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Millner L.M., Linder M.W., Valdes R., Jr. Circulating tumor cells: A review of present methods and the need to identify heterogeneous phenotypes. Ann. Clin. Lab. Sci. 2013;43:295–304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5060940</ArticleId>
            <ArticleId IdType="pubmed">23884225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J.S., Magbanua M.J.M., Park J.W. Circulating tumor cells in breast cancer: Applications in personalized medicine. Breast Cancer Res. Treat. 2016;160:411–424. doi: 10.1007/s10549-016-4014-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-016-4014-6</ArticleId>
            <ArticleId IdType="pubmed">27761678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trapp E., Janni W., Schindlbeck C., Juckstock J., Andergassen U., de Gregorio A., Alunni-Fabbroni M., Tzschaschel M., Polasik A., Koch J.G., et al.  Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. J. Natl. Cancer Inst. 2019;111:380–387. doi: 10.1093/jnci/djy152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djy152</ArticleId>
            <ArticleId IdType="pubmed">30312434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sparano J., O’Neill A., Alpaugh K., Wolff A.C., Northfelt D.W., Dang C.T., Sledge G.W., Miller K.D. Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018;4:1700–1706. doi: 10.1001/jamaoncol.2018.2574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2018.2574</ArticleId>
            <ArticleId IdType="pmc">PMC6385891</ArticleId>
            <ArticleId IdType="pubmed">30054636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall C.S., Karhade M.G., Bowman Bauldry J.B., Valad L.M., Kuerer H.M., DeSnyder S.M., Lucci A. Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients. J. Am. Coll. Surg. 2016;223:20–29. doi: 10.1016/j.jamcollsurg.2016.02.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jamcollsurg.2016.02.021</ArticleId>
            <ArticleId IdType="pmc">PMC5868486</ArticleId>
            <ArticleId IdType="pubmed">27049782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pierga J.Y., Bidard F.C., Autret A., Petit T., Andre F., Dalenc F., Levy C., Ferrero J.M., Romieu G., Bonneterre J., et al.  Circulating tumour cells and pathological complete response: Independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Ann. Oncol. 2017;28:103–109. doi: 10.1093/annonc/mdw535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdw535</ArticleId>
            <ArticleId IdType="pubmed">28177480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bidard F.C., Michiels S., Riethdorf S., Mueller V., Esserman L.J., Lucci A., Naume B., Horiguchi J., Gisbert-Criado R., Sleijfer S., et al.  Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. J. Natl. Cancer Inst. 2018;110:560–567. doi: 10.1093/jnci/djy018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djy018</ArticleId>
            <ArticleId IdType="pubmed">29659933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodman C.R., Seagle B.L., Friedl T.W.P., Rack B., Lato K., Fink V., Cristofanilli M., Donnelly E.D., Janni W., Shahabi S., et al.  Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer. JAMA Oncol. 2018;4:e180163. doi: 10.1001/jamaoncol.2018.0163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2018.0163</ArticleId>
            <ArticleId IdType="pmc">PMC6143053</ArticleId>
            <ArticleId IdType="pubmed">29800954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larsson A.M., Jansson S., Bendahl P.O., Levin Tykjaer Jorgensen C., Loman N., Graffman C., Lundgren L., Aaltonen K., Ryden L. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Res. 2018;20:48. doi: 10.1186/s13058-018-0976-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13058-018-0976-0</ArticleId>
            <ArticleId IdType="pmc">PMC5994056</ArticleId>
            <ArticleId IdType="pubmed">29884204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu X., Li F., Dang L., Liang C., Lu A., Zhang G. RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies. Front. Cell Dev. Biol. 2020;8:76. doi: 10.3389/fcell.2020.00076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2020.00076</ArticleId>
            <ArticleId IdType="pmc">PMC7026132</ArticleId>
            <ArticleId IdType="pubmed">32117996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantano F., Rossi E., Iuliani M., Facchinetti A., Simonetti S., Ribelli G., Zoccoli A., Vincenzi B., Tonini G., Zamarchi R., et al.  Dynamic changes of Receptor activator of nuclear factor-kappaB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer. Sci. Rep. 2020;10:1288. doi: 10.1038/s41598-020-58339-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-58339-2</ArticleId>
            <ArticleId IdType="pmc">PMC6987166</ArticleId>
            <ArticleId IdType="pubmed">31992773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaeger B.A., Neugebauer J., Andergassen U., Melcher C., Schochter F., Mouarrawy D., Ziemendorff G., Clemens M., Abel E.V., Heinrich G., et al.  The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial. PLoS ONE. 2017;12:e0173593.  doi: 10.1371/journal.pone.0173593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0173593</ArticleId>
            <ArticleId IdType="pmc">PMC5460789</ArticleId>
            <ArticleId IdType="pubmed">28586395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schochter F., Friedl T.W.P., deGregorio A., Krause S., Huober J., Rack B., Janni W. Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions. Cells. 2019;8:1412.  doi: 10.3390/cells8111412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8111412</ArticleId>
            <ArticleId IdType="pmc">PMC6912467</ArticleId>
            <ArticleId IdType="pubmed">31717458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kodahl A.R., Ehmsen S., Pallisgaard N., Jylling A.M.B., Jensen J.D., Laenkholm A.V., Knoop A.S., Ditzel H.J. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer. Mol. Oncol. 2018;12:925–935. doi: 10.1002/1878-0261.12305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1878-0261.12305</ArticleId>
            <ArticleId IdType="pmc">PMC5983134</ArticleId>
            <ArticleId IdType="pubmed">29689598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beaver J.A., Jelovac D., Balukrishna S., Cochran R., Croessmann S., Zabransky D.J., Wong H.Y., Toro P.V., Cidado J., Blair B.G., et al.  Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin. Cancer Res. 2014;20:2643–2650. doi: 10.1158/1078-0432.CCR-13-2933.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-2933</ArticleId>
            <ArticleId IdType="pmc">PMC4024333</ArticleId>
            <ArticleId IdType="pubmed">24504125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chandarlapaty S., Chen D., He W., Sung P., Samoila A., You D., Bhatt T., Patel P., Voi M., Gnant M., et al.  Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol. 2016;2:1310–1315. doi: 10.1001/jamaoncol.2016.1279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2016.1279</ArticleId>
            <ArticleId IdType="pmc">PMC5063698</ArticleId>
            <ArticleId IdType="pubmed">27532364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coombes R.C., Page K., Salari R., Hastings R.K., Armstrong A., Ahmed S., Ali S., Cleator S., Kenny L., Stebbing J., et al.  Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin. Cancer Res. 2019;25:4255–4263. doi: 10.1158/1078-0432.CCR-18-3663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-3663</ArticleId>
            <ArticleId IdType="pubmed">30992300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonald B.R., Contente-Cuomo T., Sammut S.J., Odenheimer-Bergman A., Ernst B., Perdigones N., Chin S.F., Farooq M., Mejia R., Cronin P.A., et al.  Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci. Transl. Med. 2019;11 doi: 10.1126/scitranslmed.aax7392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aax7392</ArticleId>
            <ArticleId IdType="pmc">PMC7236617</ArticleId>
            <ArticleId IdType="pubmed">31391323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ossandon M.R., Agrawal L., Bernhard E.J., Conley B.A., Dey S.M., Divi R.L., Guan P., Lively T.G., McKee T.C., Sorg B.S., et al.  Circulating Tumor DNA Assays in Clinical Cancer Research. J. Natl. Cancer Inst. 2018;110:929–934. doi: 10.1093/jnci/djy105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djy105</ArticleId>
            <ArticleId IdType="pmc">PMC6136923</ArticleId>
            <ArticleId IdType="pubmed">29931312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., Bartlett B.R., Wang H., Luber B., Alani R.M., et al.  Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014;6:224ra224. doi: 10.1126/scitranslmed.3007094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3007094</ArticleId>
            <ArticleId IdType="pmc">PMC4017867</ArticleId>
            <ArticleId IdType="pubmed">24553385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwarzenbach H., Stoehlmacher J., Pantel K., Goekkurt E. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann. N. Y. Acad. Sci. 2008;1137:190–196. doi: 10.1196/annals.1448.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1196/annals.1448.025</ArticleId>
            <ArticleId IdType="pubmed">18837946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Devonshire A.S., Whale A.S., Gutteridge A., Jones G., Cowen S., Foy C.A., Huggett J.F. Towards standardisation of cell-free DNA measurement in plasma: Controls for extraction efficiency, fragment size bias and quantification. Anal. Bioanal. Chem. 2014;406:6499–6512. doi: 10.1007/s00216-014-7835-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00216-014-7835-3</ArticleId>
            <ArticleId IdType="pmc">PMC4182654</ArticleId>
            <ArticleId IdType="pubmed">24853859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tangvarasittichai O., Jaiwang W., Tangvarasittichai S. The plasma DNA concentration as a potential breast cancer screening marker. Indian J. Clin. Biochem. 2015;30:55–58. doi: 10.1007/s12291-013-0407-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12291-013-0407-z</ArticleId>
            <ArticleId IdType="pmc">PMC4310844</ArticleId>
            <ArticleId IdType="pubmed">25646041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang R., Li X., Zhang H., Wang K., He J. Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker. Oncotarget. 2017;8:75742–75755. doi: 10.18632/oncotarget.20608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.20608</ArticleId>
            <ArticleId IdType="pmc">PMC5650461</ArticleId>
            <ArticleId IdType="pubmed">29088906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kruger D.T., Jansen M., Konings I., Dercksen W.M., Jager A., Oulad Hadj J., Sleijfer S., Martens J.W.M., Boven E. High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane. Mol. Oncol. 2020;14:490–503. doi: 10.1002/1878-0261.12617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1878-0261.12617</ArticleId>
            <ArticleId IdType="pmc">PMC7053245</ArticleId>
            <ArticleId IdType="pubmed">31841262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elazezy M., Joosse S.A. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput. Struct. Biotechnol. J. 2018;16:370–378. doi: 10.1016/j.csbj.2018.10.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.csbj.2018.10.002</ArticleId>
            <ArticleId IdType="pmc">PMC6197739</ArticleId>
            <ArticleId IdType="pubmed">30364656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freidin M.B., Freydina D.V., Leung M., Montero Fernandez A., Nicholson A.G., Lim E. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. Clin. Chem. 2015;61:1299–1304. doi: 10.1373/clinchem.2015.242453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1373/clinchem.2015.242453</ArticleId>
            <ArticleId IdType="pubmed">26272233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vymetalkova V., Cervena K., Bartu L., Vodicka P. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review. Int. J. Mol. Sci. 2018;19:3356.  doi: 10.3390/ijms19113356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms19113356</ArticleId>
            <ArticleId IdType="pmc">PMC6274807</ArticleId>
            <ArticleId IdType="pubmed">30373199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jenkins S., Yang J.C., Ramalingam S.S., Yu K., Patel S., Weston S., Hodge R., Cantarini M., Janne P.A., Mitsudomi T., et al.  Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. J. Thorac. Oncol. 2017;12:1061–1070. doi: 10.1016/j.jtho.2017.04.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2017.04.003</ArticleId>
            <ArticleId IdType="pubmed">28428148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y.L., Lee V., Liam C.K., Lu S., Park K., Srimuninnimit V., Wang J., Zhou C., Appius A., Button P., et al.  Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. Lung Cancer. 2018;126:1–8. doi: 10.1016/j.lungcan.2018.10.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2018.10.004</ArticleId>
            <ArticleId IdType="pubmed">30527172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heitzer E., Haque I.S., Roberts C.E.S., Speicher M.R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 2019;20:71–88. doi: 10.1038/s41576-018-0071-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41576-018-0071-5</ArticleId>
            <ArticleId IdType="pubmed">30410101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiala C., Diamandis E.P. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med. 2018;16:166.  doi: 10.1186/s12916-018-1157-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12916-018-1157-9</ArticleId>
            <ArticleId IdType="pmc">PMC6167864</ArticleId>
            <ArticleId IdType="pubmed">30285732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins M.J., Jelovac D., Barnathan E., Blair B., Slater S., Powers P., Zorzi J., Jeter S.C., Oliver G.R., Fetting J., et al.  Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin. Cancer Res. 2012;18:3462–3469. doi: 10.1158/1078-0432.CCR-11-2696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-2696</ArticleId>
            <ArticleId IdType="pmc">PMC3533370</ArticleId>
            <ArticleId IdType="pubmed">22421194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez-Saez O., Chic N., Pascual T., Adamo B., Vidal M., Gonzalez-Farre B., Sanfeliu E., Schettini F., Conte B., Braso-Maristany F., et al.  Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 2020;22:45. doi: 10.1186/s13058-020-01284-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13058-020-01284-9</ArticleId>
            <ArticleId IdType="pmc">PMC7222307</ArticleId>
            <ArticleId IdType="pubmed">32404150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen J.D., Li L., Wang Y., Thoburn C., Afsari B., Danilova L., Douville C., Javed A.A., Wong F., Mattox A., et al.  Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–930. doi: 10.1126/science.aar3247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aar3247</ArticleId>
            <ArticleId IdType="pmc">PMC6080308</ArticleId>
            <ArticleId IdType="pubmed">29348365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Board R.E., Wardley A.M., Dixon J.M., Armstrong A.C., Howell S., Renshaw L., Donald E., Greystoke A., Ranson M., Hughes A., et al.  Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res. Treat. 2010;120:461–467. doi: 10.1007/s10549-010-0747-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-010-0747-9</ArticleId>
            <ArticleId IdType="pubmed">20107891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dawson S.J., Tsui D.W., Murtaza M., Biggs H., Rueda O.M., Chin S.F., Dunning M.J., Gale D., Forshew T., Mahler-Araujo B., et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013;368:1199–1209. doi: 10.1056/NEJMoa1213261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1213261</ArticleId>
            <ArticleId IdType="pubmed">23484797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Saenz J.A., Ayllon P., Laig M., Acosta-Eyzaguirre D., Garcia-Esquinas M., Montes M., Sanz J., Barquin M., Moreno F., Garcia-Barberan V., et al.  Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. BMC Cancer. 2017;17:210.  doi: 10.1186/s12885-017-3185-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-017-3185-9</ArticleId>
            <ArticleId IdType="pmc">PMC5362993</ArticleId>
            <ArticleId IdType="pubmed">28330468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andre F., Ciruelos E., Rubovszky G., Campone M., Loibl S., Rugo H.S., Iwata H., Conte P., Mayer I.A., Kaufman B., et al.  Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N. Engl. J. Med. 2019;380:1929–1940. doi: 10.1056/NEJMoa1813904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1813904</ArticleId>
            <ArticleId IdType="pubmed">31091374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reinert T., Saad E.D., Barrios C.H., Bines J. Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer. Front. Oncol. 2017;7:26. doi: 10.3389/fonc.2017.00026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2017.00026</ArticleId>
            <ArticleId IdType="pmc">PMC5350138</ArticleId>
            <ArticleId IdType="pubmed">28361033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toy W., Shen Y., Won H., Green B., Sakr R.A., Will M., Li Z., Gala K., Fanning S., King T.A., et al.  ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 2013;45:1439–1445. doi: 10.1038/ng.2822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.2822</ArticleId>
            <ArticleId IdType="pmc">PMC3903423</ArticleId>
            <ArticleId IdType="pubmed">24185512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiavon G., Hrebien S., Garcia-Murillas I., Cutts R.J., Pearson A., Tarazona N., Fenwick K., Kozarewa I., Lopez-Knowles E., Ribas R., et al.  Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci. Transl. Med. 2015;7:313ra182. doi: 10.1126/scitranslmed.aac7551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aac7551</ArticleId>
            <ArticleId IdType="pmc">PMC4998737</ArticleId>
            <ArticleId IdType="pubmed">26560360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allouchery V., Beaussire L., Perdrix A., Sefrioui D., Augusto L., Guillemet C., Sarafan-Vasseur N., Di Fiore F., Clatot F. Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients. Breast Cancer Res. 2018;20:40. doi: 10.1186/s13058-018-0968-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13058-018-0968-0</ArticleId>
            <ArticleId IdType="pmc">PMC5956618</ArticleId>
            <ArticleId IdType="pubmed">29769099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Leary B., Hrebien S., Beaney M., Fribbens C., Garcia-Murillas I., Jiang J., Li Y., Huang Bartlett C., Andre F., Loibl S., et al.  Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. Clin. Chem. 2019;65:1405–1413. doi: 10.1373/clinchem.2019.305805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1373/clinchem.2019.305805</ArticleId>
            <ArticleId IdType="pubmed">31551314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oxnard G.R., Thress K.S., Alden R.S., Lawrance R., Paweletz C.P., Cantarini M., Yang J.C., Barrett J.C., Janne P.A. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2016;34:3375–3382. doi: 10.1200/JCO.2016.66.7162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.66.7162</ArticleId>
            <ArticleId IdType="pmc">PMC5035123</ArticleId>
            <ArticleId IdType="pubmed">27354477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spoerke J.M., Gendreau S., Walter K., Qiu J., Wilson T.R., Savage H., Aimi J., Derynck M.K., Chen M., Chan I.T., et al.  Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat. Commun. 2016;7:11579. doi: 10.1038/ncomms11579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms11579</ArticleId>
            <ArticleId IdType="pmc">PMC4869259</ArticleId>
            <ArticleId IdType="pubmed">27174596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Couraud S., Vaca-Paniagua F., Villar S., Oliver J., Schuster T., Blanche H., Girard N., Tredaniel J., Guilleminault L., Gervais R., et al.  Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: A proof-of-concept study from BioCAST/IFCT-1002. Clin. Cancer Res. 2014;20:4613–4624. doi: 10.1158/1078-0432.CCR-13-3063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-3063</ArticleId>
            <ArticleId IdType="pubmed">25013125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narayan A., Carriero N.J., Gettinger S.N., Kluytenaar J., Kozak K.R., Yock T.I., Muscato N.E., Ugarelli P., Decker R.H., Patel A.A. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res. 2012;72:3492–3498. doi: 10.1158/0008-5472.CAN-11-4037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-4037</ArticleId>
            <ArticleId IdType="pmc">PMC3426449</ArticleId>
            <ArticleId IdType="pubmed">22581825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reinert T., Henriksen T.V., Christensen E., Sharma S., Salari R., Sethi H., Knudsen M., Nordentoft I., Wu H.T., Tin A.S., et al.  Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019 doi: 10.1001/jamaoncol.2019.0528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2019.0528</ArticleId>
            <ArticleId IdType="pmc">PMC6512280</ArticleId>
            <ArticleId IdType="pubmed">31070691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abbosh C., Birkbak N.J., Wilson G.A., Jamal-Hanjani M., Constantin T., Salari R., Le Quesne J., Moore D.A., Veeriah S., Rosenthal R., et al.  Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446–451. doi: 10.1038/nature22364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature22364</ArticleId>
            <ArticleId IdType="pmc">PMC5812436</ArticleId>
            <ArticleId IdType="pubmed">28445469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christensen E., Birkenkamp-Demtroder K., Sethi H., Shchegrova S., Salari R., Nordentoft I., Wu H.T., Knudsen M., Lamy P., Lindskrog S.V., et al.  Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients with Urothelial Bladder Carcinoma. J. Clin. Oncol. 2019;37:1547–1557. doi: 10.1200/JCO.18.02052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.18.02052</ArticleId>
            <ArticleId IdType="pubmed">31059311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Mattos-Arruda L., Weigelt B., Cortes J., Won H.H., Ng C.K.Y., Nuciforo P., Bidard F.C., Aura C., Saura C., Peg V., et al.  Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: A proof-of-principle. Ann. Oncol. 2014;25:1729–1735. doi: 10.1093/annonc/mdu239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdu239</ArticleId>
            <ArticleId IdType="pmc">PMC6276937</ArticleId>
            <ArticleId IdType="pubmed">25009010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalluri R., LeBleu V.S. The biology, function, and biomedical applications of exosomes. Science. 2020;367 doi: 10.1126/science.aau6977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aau6977</ArticleId>
            <ArticleId IdType="pmc">PMC7717626</ArticleId>
            <ArticleId IdType="pubmed">32029601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hessvik N.P., Llorente A. Current knowledge on exosome biogenesis and release. Cell Mol. Life Sci. 2018;75:193–208. doi: 10.1007/s00018-017-2595-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-017-2595-9</ArticleId>
            <ArticleId IdType="pmc">PMC5756260</ArticleId>
            <ArticleId IdType="pubmed">28733901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai J., Su Y., Zhong S., Cong L., Liu B., Yang J., Tao Y., He Z., Chen C., Jiang Y. Exosomes: Key players in cancer and potential therapeutic strategy. Signal. Transduct. Target. Ther. 2020;5:145. doi: 10.1038/s41392-020-00261-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-00261-0</ArticleId>
            <ArticleId IdType="pmc">PMC7406508</ArticleId>
            <ArticleId IdType="pubmed">32759948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azmi A.S., Bao B., Sarkar F.H. Exosomes in cancer development, metastasis, and drug resistance: A comprehensive review. Cancer Metastasis Rev. 2013;32:623–642. doi: 10.1007/s10555-013-9441-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-013-9441-9</ArticleId>
            <ArticleId IdType="pmc">PMC3843988</ArticleId>
            <ArticleId IdType="pubmed">23709120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>King H.W., Michael M.Z., Gleadle J.M. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer. 2012;12:421.  doi: 10.1186/1471-2407-12-421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-12-421</ArticleId>
            <ArticleId IdType="pmc">PMC3488584</ArticleId>
            <ArticleId IdType="pubmed">22998595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parolini I., Federici C., Raggi C., Lugini L., Palleschi S., De Milito A., Coscia C., Iessi E., Logozzi M., Molinari A., et al.  Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem. 2009;284:34211–34222. doi: 10.1074/jbc.M109.041152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M109.041152</ArticleId>
            <ArticleId IdType="pmc">PMC2797191</ArticleId>
            <ArticleId IdType="pubmed">19801663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McAndrews K.M., Kalluri R. Mechanisms associated with biogenesis of exosomes in cancer. Mol. Cancer. 2019;18:52. doi: 10.1186/s12943-019-0963-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-019-0963-9</ArticleId>
            <ArticleId IdType="pmc">PMC6441149</ArticleId>
            <ArticleId IdType="pubmed">30925917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LeBleu V.S., Kalluri R. Exosomes as a Multicomponent Biomarker Platform in Cancer. Trends Cancer. 2020;6:767–774. doi: 10.1016/j.trecan.2020.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trecan.2020.03.007</ArticleId>
            <ArticleId IdType="pubmed">32307267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou B., Xu K., Zheng X., Chen T., Wang J., Song Y., Shao Y., Zheng S. Application of exosomes as liquid biopsy in clinical diagnosis. Signal. Transduct. Target. Ther. 2020;5:144. doi: 10.1038/s41392-020-00258-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-00258-9</ArticleId>
            <ArticleId IdType="pmc">PMC7400738</ArticleId>
            <ArticleId IdType="pubmed">32747657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Logozzi M., Mizzoni D., Di Raimo R., Fais S. Exosomes: A Source for New and Old Biomarkers in Cancer. Cancers (Basel) 2020;12:2566.  doi: 10.3390/cancers12092566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12092566</ArticleId>
            <ArticleId IdType="pmc">PMC7565506</ArticleId>
            <ArticleId IdType="pubmed">32916840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X., Xie F., Wang L., Zhang L., Zhang S., Fang M., Zhou F. The function and clinical application of extracellular vesicles in innate immune regulation. Cell Mol. Immunol. 2020;17:323–334. doi: 10.1038/s41423-020-0391-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41423-020-0391-1</ArticleId>
            <ArticleId IdType="pmc">PMC7109106</ArticleId>
            <ArticleId IdType="pubmed">32203193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia Y., Chen Y., Wang Q., Jayasinghe U., Luo X., Wei Q., Wang J., Xiong H., Chen C., Xu B., et al.  Exosome: Emerging biomarker in breast cancer. Oncotarget. 2017;8:41717–41733. doi: 10.18632/oncotarget.16684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.16684</ArticleId>
            <ArticleId IdType="pmc">PMC5522217</ArticleId>
            <ArticleId IdType="pubmed">28402944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Y., Sun J., Wang X., Hu T., Ma Y., Kong C., Piao H., Yu T., Zhang G. Exosomes: A Promising Avenue for the Diagnosis of Breast Cancer. Technol. Cancer Res. Treat. 2019;18:1533033818821421. doi: 10.1177/1533033818821421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1533033818821421</ArticleId>
            <ArticleId IdType="pmc">PMC6373987</ArticleId>
            <ArticleId IdType="pubmed">30760122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007;9:654–659. doi: 10.1038/ncb1596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1596</ArticleId>
            <ArticleId IdType="pubmed">17486113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hannafon B.N., Trigoso Y.D., Calloway C.L., Zhao Y.D., Lum D.H., Welm A.L., Zhao Z.J., Blick K.E., Dooley W.C., Ding W.Q. Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res. 2016;18:90. doi: 10.1186/s13058-016-0753-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13058-016-0753-x</ArticleId>
            <ArticleId IdType="pmc">PMC5016889</ArticleId>
            <ArticleId IdType="pubmed">27608715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eichelser C., Stuckrath I., Muller V., Milde-Langosch K., Wikman H., Pantel K., Schwarzenbach H. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget. 2014;5:9650–9663. doi: 10.18632/oncotarget.2520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.2520</ArticleId>
            <ArticleId IdType="pmc">PMC4259427</ArticleId>
            <ArticleId IdType="pubmed">25333260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stevic I., Muller V., Weber K., Fasching P.A., Karn T., Marme F., Schem C., Stickeler E., Denkert C., van Mackelenbergh M., et al.  Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med. 2018;16:179.  doi: 10.1186/s12916-018-1163-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12916-018-1163-y</ArticleId>
            <ArticleId IdType="pmc">PMC6178264</ArticleId>
            <ArticleId IdType="pubmed">30301470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez-Martinez A., de Miguel-Perez D., Ortega F.G., Garcia-Puche J.L., Robles-Fernandez I., Exposito J., Martorell-Marugan J., Carmona-Saez P., Garrido-Navas M.D.C., Rolfo C., et al.  Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy. Breast Cancer Res. 2019;21:21. doi: 10.1186/s13058-019-1109-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13058-019-1109-0</ArticleId>
            <ArticleId IdType="pmc">PMC6366103</ArticleId>
            <ArticleId IdType="pubmed">30728048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sueta A., Yamamoto Y., Tomiguchi M., Takeshita T., Yamamoto-Ibusuki M., Iwase H. Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence. Oncotarget. 2017;8:69934–69944. doi: 10.18632/oncotarget.19482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.19482</ArticleId>
            <ArticleId IdType="pmc">PMC5642528</ArticleId>
            <ArticleId IdType="pubmed">29050253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshikawa M., Iinuma H., Umemoto Y., Yanagisawa T., Matsumoto A., Jinno H. Exosome-encapsulated microRNA-223-3p as a minimally invasive biomarker for the early detection of invasive breast cancer. Oncol. Lett. 2018;15:9584–9592. doi: 10.3892/ol.2018.8457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2018.8457</ArticleId>
            <ArticleId IdType="pmc">PMC5958689</ArticleId>
            <ArticleId IdType="pubmed">29805680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschfeld M., Rucker G., Weiss D., Berner K., Ritter A., Jager M., Erbes T. Urinary Exosomal MicroRNAs as Potential Non-invasive Biomarkers in Breast Cancer Detection. Mol. Diagn Ther. 2020;24:215–232. doi: 10.1007/s40291-020-00453-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40291-020-00453-y</ArticleId>
            <ArticleId IdType="pubmed">32112368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez M., Silva J., Herrera A., Herrera M., Pena C., Martin P., Gil-Calderon B., Larriba M.J., Coronado M.J., Soldevilla B., et al.  Exosomes enriched in stemness/metastatic-related mRNAS promote oncogenic potential in breast cancer. Oncotarget. 2015;6:40575–40587. doi: 10.18632/oncotarget.5818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.5818</ArticleId>
            <ArticleId IdType="pmc">PMC4747353</ArticleId>
            <ArticleId IdType="pubmed">26528758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang S.J., Wang D.D., Li J., Xu H.Z., Shen H.Y., Chen X., Zhou S.Y., Zhong S.L., Zhao J.H., Tang J.H. Predictive role of GSTP1-containing exosomes in chemotherapy-resistant breast cancer. Gene. 2017;623:5–14. doi: 10.1016/j.gene.2017.04.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2017.04.031</ArticleId>
            <ArticleId IdType="pubmed">28438694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Re M., Bertolini I., Crucitta S., Fontanelli L., Rofi E., De Angelis C., Diodati L., Cavallero D., Gianfilippo G., Salvadori B., et al.  Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients. Breast Cancer Res. Treat. 2019;178:57–62. doi: 10.1007/s10549-019-05365-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-019-05365-y</ArticleId>
            <ArticleId IdType="pubmed">31346846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang S., Zheng K., Tang Y., Li Z., Zou T., Liu D. Overexpression of serum exosomal HOTAIR is correlated with poor survival and poor response to chemotherapy in breast cancer patients. J. Biosci. 2019;44:37. doi: 10.1007/s12038-019-9861-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12038-019-9861-y</ArticleId>
            <ArticleId IdType="pubmed">31180050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong G., Wang K., Li J., Xiao S., Wei W., Liu J. Determination of Serum Exosomal H19 as a Noninvasive Biomarker for Breast Cancer Diagnosis. Onco Targets Ther. 2020;13:2563–2571. doi: 10.2147/OTT.S243601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S243601</ArticleId>
            <ArticleId IdType="pmc">PMC7109356</ArticleId>
            <ArticleId IdType="pubmed">32273726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong H., Wang W., Chen R., Zhang Y., Zou K., Ye M., He X., Zhang F., Han J. Exosome-mediated transfer of lncRNASNHG14 promotes trastuzumab chemoresistance in breast cancer. Int. J. Oncol. 2018;53:1013–1026. doi: 10.3892/ijo.2018.4467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2018.4467</ArticleId>
            <ArticleId IdType="pmc">PMC6065402</ArticleId>
            <ArticleId IdType="pubmed">30015837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X., Zhong W., Bu J., Li Y., Li R., Nie R., Xiao C., Ma K., Huang X., Li Y. Exosomal protein CD82 as a diagnostic biomarker for precision medicine for breast cancer. Mol. Carcinog. 2019;58:674–685. doi: 10.1002/mc.22960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.22960</ArticleId>
            <ArticleId IdType="pubmed">30604894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clayton A., Turkes A., Navabi H., Mason M.D., Tabi Z. Induction of heat shock proteins in B-cell exosomes. J. Cell Sci. 2005;118:3631–3638. doi: 10.1242/jcs.02494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.02494</ArticleId>
            <ArticleId IdType="pubmed">16046478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciocca D.R., Calderwood S.K. Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10:86–103. doi: 10.1379/CSC-99r.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1379/CSC-99r.1</ArticleId>
            <ArticleId IdType="pmc">PMC1176476</ArticleId>
            <ArticleId IdType="pubmed">16038406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chanteloup G., Cordonnier M., Isambert N., Bertaut A., Hervieu A., Hennequin A., Luu M., Zanetta S., Coudert B., Bengrine L., et al.  Monitoring HSP70 exosomes in cancer patients’ follow up: A clinical prospective pilot study. J. Extracell Vesicles. 2020;9:1766192. doi: 10.1080/20013078.2020.1766192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/20013078.2020.1766192</ArticleId>
            <ArticleId IdType="pmc">PMC7301715</ArticleId>
            <ArticleId IdType="pubmed">32595915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moon P.G., Lee J.E., Cho Y.E., Lee S.J., Chae Y.S., Jung J.H., Kim I.S., Park H.Y., Baek M.C. Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer. Oncotarget. 2016;7:40189–40199. doi: 10.18632/oncotarget.9561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.9561</ArticleId>
            <ArticleId IdType="pmc">PMC5130002</ArticleId>
            <ArticleId IdType="pubmed">27250024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moon P.G., Lee J.E., Cho Y.E., Lee S.J., Jung J.H., Chae Y.S., Bae H.I., Kim Y.B., Kim I.S., Park H.Y., et al.  Identification of Developmental Endothelial Locus-1 on Circulating Extracellular Vesicles as a Novel Biomarker for Early Breast Cancer Detection. Clin. Cancer Res. 2016;22:1757–1766. doi: 10.1158/1078-0432.CCR-15-0654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-0654</ArticleId>
            <ArticleId IdType="pubmed">26603257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J.E., Moon P.G., Cho Y.E., Kim Y.B., Kim I.S., Park H., Baek M.C. Identification of EDIL3 on extracellular vesicles involved in breast cancer cell invasion. J. Proteom. 2016;131:17–28. doi: 10.1016/j.jprot.2015.10.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jprot.2015.10.005</ArticleId>
            <ArticleId IdType="pubmed">26463135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan S., Bennit H.F., Turay D., Perez M., Mirshahidi S., Yuan Y., Wall N.R. Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC Cancer. 2014;14:176.  doi: 10.1186/1471-2407-14-176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-14-176</ArticleId>
            <ArticleId IdType="pmc">PMC3995700</ArticleId>
            <ArticleId IdType="pubmed">24620748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melo S.A., Luecke L.B., Kahlert C., Fernandez A.F., Gammon S.T., Kaye J., LeBleu V.S., Mittendorf E.A., Weitz J., Rahbari N., et al.  Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523:177–182. doi: 10.1038/nature14581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14581</ArticleId>
            <ArticleId IdType="pmc">PMC4825698</ArticleId>
            <ArticleId IdType="pubmed">26106858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rupp A.K., Rupp C., Keller S., Brase J.C., Ehehalt R., Fogel M., Moldenhauer G., Marme F., Sultmann H., Altevogt P. Loss of EpCAM expression in breast cancer derived serum exosomes: Role of proteolytic cleavage. Gynecol. Oncol. 2011;122:437–446. doi: 10.1016/j.ygyno.2011.04.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2011.04.035</ArticleId>
            <ArticleId IdType="pubmed">21601258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang S., Tian H., Li X., Jin D., Li X., Kong J., Yang C., Yang X., Lu Y., Luo Y., et al.  Clinical application of a microfluidic chip for immunocapture and quantification of circulating exosomes to assist breast cancer diagnosis and molecular classification. PLoS ONE. 2017;12:e0175050.  doi: 10.1371/journal.pone.0175050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0175050</ArticleId>
            <ArticleId IdType="pmc">PMC5378374</ArticleId>
            <ArticleId IdType="pubmed">28369094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen I.H., Xue L., Hsu C.C., Paez J.S., Pan L., Andaluz H., Wendt M.K., Iliuk A.B., Zhu J.K., Tao W.A. Phosphoproteins in extracellular vesicles as candidate markers for breast cancer. Proc. Natl. Acad. Sci. USA. 2017;114:3175–3180. doi: 10.1073/pnas.1618088114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1618088114</ArticleId>
            <ArticleId IdType="pmc">PMC5373352</ArticleId>
            <ArticleId IdType="pubmed">28270605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amorim M., Fernandes G., Oliveira P., Martins-de-Souza D., Dias-Neto E., Nunes D. The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles. Proteomics. 2014;14:1472–1479. doi: 10.1002/pmic.201300485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pmic.201300485</ArticleId>
            <ArticleId IdType="pubmed">24733759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciravolo V., Huber V., Ghedini G.C., Venturelli E., Bianchi F., Campiglio M., Morelli D., Villa A., Della Mina P., Menard S., et al.  Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J. Cell Physiol. 2012;227:658–667. doi: 10.1002/jcp.22773.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.22773</ArticleId>
            <ArticleId IdType="pubmed">21465472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rontogianni S., Synadaki E., Li B., Liefaard M.C., Lips E.H., Wesseling J., Wu W., Altelaar M. Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping. Commun. Biol. 2019;2:325. doi: 10.1038/s42003-019-0570-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s42003-019-0570-8</ArticleId>
            <ArticleId IdType="pmc">PMC6722120</ArticleId>
            <ArticleId IdType="pubmed">31508500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ning K., Wang T., Sun X., Zhang P., Chen Y., Jin J., Hua D. UCH-L1-containing exosomes mediate chemotherapeutic resistance transfer in breast cancer. J. Surg. Oncol. 2017;115:932–940. doi: 10.1002/jso.24614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jso.24614</ArticleId>
            <ArticleId IdType="pubmed">28334432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma X., Chen Z., Hua D., He D., Wang L., Zhang P., Wang J., Cai Y., Gao C., Zhang X., et al.  Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance. Proc. Natl. Acad. Sci. USA. 2014;111:6389–6394. doi: 10.1073/pnas.1400272111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1400272111</ArticleId>
            <ArticleId IdType="pmc">PMC4035923</ArticleId>
            <ArticleId IdType="pubmed">24733904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T., Ning K., Lu T.X., Sun X., Jin L., Qi X., Jin J., Hua D. Increasing circulating exosomes-carrying TRPC5 predicts chemoresistance in metastatic breast cancer patients. Cancer Sci. 2017;108:448–454. doi: 10.1111/cas.13150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.13150</ArticleId>
            <ArticleId IdType="pmc">PMC5378269</ArticleId>
            <ArticleId IdType="pubmed">28032400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bossuyt P.M. Clinical validity: Defining biomarker performance. Scand. J. Clin. Lab. Invest. Suppl. 2010;242:46–52. doi: 10.3109/00365513.2010.493383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/00365513.2010.493383</ArticleId>
            <ArticleId IdType="pubmed">20515277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pletcher M.J., Pignone M. Evaluating the clinical utility of a biomarker: A review of methods for estimating health impact. Circulation. 2011;123:1116–1124. doi: 10.1161/CIRCULATIONAHA.110.943860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.943860</ArticleId>
            <ArticleId IdType="pmc">PMC3138723</ArticleId>
            <ArticleId IdType="pubmed">21403122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heidrich I., Ackar L., Mossahebi Mohammadi P., Pantel K. Liquid biopsies: Potential and challenges. Int. J. Cancer. 2020 doi: 10.1002/ijc.33217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.33217</ArticleId>
            <ArticleId IdType="pubmed">32683679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chi K.R. The tumour trail left in blood. Nature. 2016;532:269–271. doi: 10.1038/532269a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/532269a</ArticleId>
            <ArticleId IdType="pubmed">27075102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barriere G., Fici P., Gallerani G., Fabbri F., Zoli W., Rigaud M. Circulating tumor cells and epithelial, mesenchymal and stemness markers: Characterization of cell subpopulations. Ann. Transl. Med. 2014;2:109. doi: 10.3978/j.issn.2305-5839.2014.10.04.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3978/j.issn.2305-5839.2014.10.04</ArticleId>
            <ArticleId IdType="pmc">PMC4245517</ArticleId>
            <ArticleId IdType="pubmed">25489583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prieto-Garcia E., Diaz-Garcia C.V., Garcia-Ruiz I., Agullo-Ortuno M.T. Epithelial-to-mesenchymal transition in tumor progression. Med. Oncol. 2017;34:122. doi: 10.1007/s12032-017-0980-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12032-017-0980-8</ArticleId>
            <ArticleId IdType="pubmed">28560682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nieto M.A., Huang R.Y., Jackson R.A., Thiery J.P. Emt: 2016. Cell. 2016;166:21–45. doi: 10.1016/j.cell.2016.06.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.06.028</ArticleId>
            <ArticleId IdType="pubmed">27368099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibue T., Weinberg R.A. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 2017;14:611–629. doi: 10.1038/nrclinonc.2017.44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2017.44</ArticleId>
            <ArticleId IdType="pmc">PMC5720366</ArticleId>
            <ArticleId IdType="pubmed">28397828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyun K.A., Koo G.B., Han H., Sohn J., Choi W., Kim S.I., Jung H.I., Kim Y.S. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer. Oncotarget. 2016;7:24677–24687. doi: 10.18632/oncotarget.8250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.8250</ArticleId>
            <ArticleId IdType="pmc">PMC5029733</ArticleId>
            <ArticleId IdType="pubmed">27013581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ignatiadis M., Rothe F., Chaboteaux C., Durbecq V., Rouas G., Criscitiello C., Metallo J., Kheddoumi N., Singhal S.K., Michiels S., et al.  HER2-positive circulating tumor cells in breast cancer. PLoS ONE. 2011;6:e15624.  doi: 10.1371/journal.pone.0015624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0015624</ArticleId>
            <ArticleId IdType="pmc">PMC3018524</ArticleId>
            <ArticleId IdType="pubmed">21264346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho M.S., Park C.H., Lee S., Park H.S. Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation. PLoS ONE. 2020;15:e0230622.  doi: 10.1371/journal.pone.0230622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0230622</ArticleId>
            <ArticleId IdType="pmc">PMC7083310</ArticleId>
            <ArticleId IdType="pubmed">32196518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johansson G., Andersson D., Filges S., Li J., Muth A., Godfrey T.E., Stahlberg A. Considerations and quality controls when analyzing cell-free tumor DNA. Biomol. Detect. Quantif. 2019;17:100078. doi: 10.1016/j.bdq.2018.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bdq.2018.12.003</ArticleId>
            <ArticleId IdType="pmc">PMC6416156</ArticleId>
            <ArticleId IdType="pubmed">30906693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stetson D., Ahmed A., Xu X., Nuttall B.R., Lubinski T.J., Johnson J.H., Barrett J.C., Dougherty B.A. Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance. JCO Precis. Oncol. 2019 doi: 10.1200/PO.18.00191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/PO.18.00191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gandham S., Su X., Wood J., Nocera A.L., Alli S.C., Milane L., Zimmerman A., Amiji M., Ivanov A.R. Technologies and Standardization in Research on Extracellular Vesicles. Trends Biotechnol. 2020;38:1066–1098. doi: 10.1016/j.tibtech.2020.05.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibtech.2020.05.012</ArticleId>
            <ArticleId IdType="pmc">PMC7302792</ArticleId>
            <ArticleId IdType="pubmed">32564882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tellez-Gabriel M., Heymann D. Exosomal lncRNAs: The newest promising liquid biopsy. Cancer Drug Resist. 2019 doi: 10.20517/cdr.2019.69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.20517/cdr.2019.69</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye Z., Wang C., Wan S., Mu Z., Zhang Z., Abu-Khalaf M.M., Fellin F.M., Silver D.P., Neupane M., Jaslow R.J., et al.  Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. Eur. J. Cancer. 2019;106:133–143. doi: 10.1016/j.ejca.2018.10.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2018.10.012</ArticleId>
            <ArticleId IdType="pmc">PMC6347110</ArticleId>
            <ArticleId IdType="pubmed">30528798</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
